VISCHER advises EyeSense AG in Basel in its multi-million Series B Financing Round led by Rosetta Capital and supported by existing investors as well as Lee’s Pharmaceutical (Lee’s PHARM - Hong Kong Stock Exchange) as a new investor. The new funds will mainly support an expansion of the availability of innovative continuous blood glucose monitoring systems to further improve and individualize the treatment of the steadily growing number of diabetes patients. The VISCHER Team is lead by Dr. Matthias Staehelin (Partner) with Mathias Kuster (Senior Associate), both Corporate.